- Open Access
TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway
- Guohe Song†1,
- Shifeng Xu†2,
- Hong Zhang3,
- Yupeng Wang1,
- Chao Xiao1,
- Tao Jiang1,
- Leilei Wu4,
- Tao Zhang1,
- Xing Sun1,
- Lin Zhong1,
- Chongzhi Zhou1,
- Zhaowen Wang1,
- Zhihai Peng1,
- Jian Chen1Email author and
- Xiaoliang Wang1Email author
© The Author(s). 2016
- Received: 4 July 2016
- Accepted: 14 September 2016
- Published: 20 September 2016
Tissue inhibitor matrix metalloproteinase 1 (TIMP1) plays a vital role in carcinogenesis, yet its precise functional roles and regulation remain unclear. In this study, we aim to investigate its biological function and clinical significance in human colon cancer.
We analyzed the expression of TIMP1 in both public database (Oncomine and TCGA) and 94 cases of primary colon cancer and matched normal colon tissue specimens. The underlying mechanisms of altered TIMP1 expression on cell tumorigenesis, proliferation, and metastasis were explored in vitro and in vivo.
TIMP1 was overexpressed in colon tumorous tissues and lymph node metastasis specimens than in normal tissues. The aberrant expression of TIMP1 was significantly associated with the regional lymph node metastasis (p = 0.033), distant metastasis (p = 0.039), vascular invasion (p = 0.024) and the American Joint Committee on Cancer (AJCC) stage (p = 0.026). Cox proportional hazards model showed that TIMP1 was an independent prognostic indicator of disease-free survival (HR = 2.603, 95 % CI: 1.115–6.077, p = 0.027) and overall survival (HR = 2.907, 95 % CI: 1.254–6.737, p = 0.013) for patients with colon cancer. Consistent with this, our findings highlight that suppression of TIMP1 expression decreased proliferation, and metastasis but increased apoptosis by inducing TIMP1 specific regulated FAK-PI3K/AKT and MAPK pathway.
TIMP1 might play an important role in promoting tumorigenesis and metastasis of human colon cancer and function as a potential prognostic indicator for colon cancer.
- Colon cancer
Colon cancer represents one of the most common malignancies worldwide and a common cause of morbidity and mortality . Despite increased treatment advances in the past 20 years, early diagnosis can still improve the prognosis of this disease . Molecular studies have revealed a large number of genetic alterations that occur during colon carcinogenesis, however, precise genetic changes responsible for the occurrence and progression of colon cancer is still poorly understood [3, 4]. Therefore, identification of molecular markers remains crucial for designing novel and efficient treatment strategy.
Tissue inhibitor matrix metalloproteinase 1 (TIMP1), located on chromosome Xp11.3-p11.23, belongs to the Tissue Inhibitor of Metalloproteinases family which included four identified members (TIMP1, TIMP2, TIMP3, and TIMP4). TIMP1 encodes a 931 base-pair mRNA and a 207 amino acid protein. Studies have shown that this protein may inhibit the proteolytic activity of matrix metalloproteinases (MMPs) by forming noncovalent 1:1 stoichiometric complexes and regulate the balance of matrix remodeling during degradation of extracellular matrix . In addition to its inhibitory effect on most of the known MMPs, which are thought to be crucial for the tumor invasion and development of metastatic disease , TIMPs also play an important role in the regulation of cell proliferation and anti-apoptotic function [7–9]. Studies in vitro have demonstrated that overexpression of TIMP1 can lead to a substantially increase of genes involved in proliferation, apoptosis and signal transduction . In addition, TIMP1 was found to decrease tumor cell sensitivity to multiple anticancer drugs by activation of downstream pathways and exhibited anti-apoptotic activity. Specifically, the TIMP1 could degrade cyclinB1 and activate the NF-kβ signaling pathway to protect breast cancer cells against chemotherapy-induced cell death . In particular, it has also been demonstrated that TIMP1 might bind to the CD63/integrin β1 complex causing anti-apoptotic effects .
Recently, clinical studies have shown that the aberrant expression of TIMP1 is associated with an unfavorable prognosis in a series of tumors, such as gastric cancer , papillary thyroid carcinoma , cutaneous melanoma  and breast cancer . The expression level of TIMP1 often correlates with the TNM stage, disease-free survival, the rate of tumor recurrence and even the extent of liver metastasis. Furthermore, TIMP1 is a secretory protein that could be detected in blood and body fluid by enzyme linked immunosorbent assay (ELISA). The expression level of TIMP1 was significantly increased in the blood of patients with gastric cancer  and familial pancreatic cancer , which could make it as a potential serum marker. However, the precise function and underlying mechanisms of TIMP1 remain to be elucidated in colon cancer.
In the present study, we investigate the expression of TIMP1 at the mRNA and protein level in human colon cancer and clarify the correlation between the TIMP1 expression and clinicopathological parameters. We also sought to determine the role of TIMP1 in colon cancer cell biological function and the underlying molecular mechanisms.
Patient information and clinical specimens
A total of 94 patients who had surgery for colon cancer between January 2007 and December 2009 at the Shanghai General Hospital were selected for this study. This study was approved by the Institutional Research Ethics Committee of Shanghai General Hospital. Patients received neither chemotherapy nor radiotherapy before surgery. There were 47 male and 47 female with a median age of 67 years (range, 36–92 years) at the time of operation. The tumor stage classification was determined by at least two pathologists who were blinded to the data according to the American Joint Committee on Cancer (AJCC). Disease-free survival (DFS) and overall survival (OS) rates were defined as the interval from initial surgery to clinically or radiologically proven recurrence/metastasis and death, respectively. Cancer tissues and metastatic lymph nodes obtained from patients were immediately fixed in formalin and embedded in paraffin for immunohistochemical (IHC) studies after dehydration. Fresh samples were dissected manually and were immediately stored in liquid nitrogen until western blot analysis. Written and informed consent was obtained from all patients before enrollment in the study.
The Oncomine,Cancer Genome Atlas (TCGA) and Protein-Protein Interaction (PPI) network
Oncomine (www.oncomine.org) was used to acquire TIMP1 RNA expression in colon carcinoma and normal mucosae. TCGA RNA-Seq (level 3) and corresponding clinical data were downloaded from TCGA website (https://tcga-data.nci.nih.gov/tcga/) following approval of this project by the consortium. RNA-Seq analysis used data from 45 stage I, 108 stage II, 80 stage III and 38 stage IV colon cancers and 40 adjacent normal tissues. To further analyze the function of the significant biomarkers, the Retrieval of Interacting Genes/Proteins (STRING database v10.0) resource was utilized for PPI network analysis and prediction of protein-protein interactions. Proteins were linked based on the following six criteria: neighborhood, gene fusion, co-occurrence, co-expression, experimental evidence and existing databases. A p value of less than 0.05 was considered as the cut-off criterion. TIMP1’s PPI network containing the top 20 confident proteins were built in Additional file 1: Figure S1.
Gene Set Enrichment Analysis (GSEA)
GSEA is a method of analyzing and interpreting microarray and such data using biological knowledge. The data firstly generated an ordered list of all genes according to their correlation with TIMP1 expression, and then a predefined gene set receives an enrichment score (ES), which is a measure of statistical evidence rejecting the null hypothesis that its members are randomly distributed in the ordered list. GSEA was performed using The Cancer Genome Atlas (TCGA) colorectal cancer (CRC) dataset by GSEA version 2.2 from the Broad Institute at MIT.
Western blot assays
Total protein was extracted from colon tumors and their adjacent normal tissues of 4 patients using RIPA lysis buffer with inhibitor phenylmethanesulfonyl fluoride (PMSF) and then the concentration was measured with BCA protein assay kit (Beyotime Biotechnology, Jiangsu, China). Equal amounts of protein (30 μg) were subjected to 10 % sodium dodecyl sulfate-polyacrylamide gelelectrophoresis and then transferred onto PVDF membranes. The membranes were blocked in 5 % non-fat milk with 0.1 % Tween for 1 h at room temperature followed by incubating at 4 ∘C overnight with primary rabbit polyclonal antibody against human protein TIMP1 (1:1000 dilution, Abcam, USA) and β-actin (1:1000 dilution, Abcam, USA). After washing with TBST buffer, the membrane was incubated with secondary antibodies conjugated to horseradish peroxidase. The anti-β-actin antibody was used as loading controls. The proteins were detected by ECL chemiluminescence kit (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer’s instructions.
Sections (4-μm thick) were blocked with 3 % H2O2 after dewaxing and rehydrating in a graded series of ethanol. Then, pressure cooker mediated antigen retrieval process was performed in 0.01 M sodium citrate solution (pH 6.0) and the expression of TIMP1 was tested using standard immunohistochemical methods . The corresponding primary antibody was used as follows,TIMP1 (1:100 dilution, Abcam, USA). Immunoreactivity was evaluated independently by two pathologists who were blinded to patient information. The evaluation was based on the staining intensity and the area of staining. The staining intensity was graded as follows: 0, no staining; 1, mild staining; 2, moderate staining; and 3, intense staining. The staining area was scored as follows: 0, no staining of cells; 1, 1–25 %; 2, 26–50 %; 3, 51–75 %; and 4, 76–100 %. The sum of staining score (intensity and extension) index was used as the final staining score, graded as follows: 0–1, negative expression; 2–4, weakly positive expression; and 5–6, strongly positive expression. Weakly positive and strongly positive were considered as positive.
Plasmids construction, transfections and lentiviral transduction
The control shRNA lentivirus, and TIMP1 shRNA lentivirus were all constructed by Shanghai Genechem Medical Biotechnology Company.
siRNA-Control Target: AATTCTCCGAACGTGTCACGT;
siRNA-TIMP-1 Target: ATCAACCAGACCACCTTATA;
For lentivirus transfections, colon cancer cells were transfected with 5 μg of lenti-TIMP1-virus or lenti-control virus. Methods used for lentivirus production and infection were performed as described previously .
RNA extraction, reverse transcription PCR and quantitative real-time PCR (qPCR)
Total RNA was prepared from cell cultures using TRIzol reagent (TaKaRa, Japan) according to the manufacturer’s instructions. First strand cDNA was synthesized from 2 μg of total RNA using RevertAid™First Strand cDNA Synthesis Kit (Fermentas, USA). The quantitative real-time PCR primers were provided by Sheng Gong Company. The sequences of forward and reverse primers are used as follows:
The reaction was performed for 40 cycles of 95 °C for 2 min, and then 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 30 s, with a final extension at 72 °C for 30 s. Relative quantities (Δ cycle threshold (Ct) value) were obtained by normalizing to β-actin. Each reaction was performed in triplicate.
Cell proliferation and plate colony formation assays
Cells were seeded into 96-well plates (2000 cells per well), cultured for 24 h, and then measured using 10 μl Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Japan) in 100 μl medium per well for 1 h at 37 °C, and then absorbance was measured at 450 nm. For plate colony formation assays, 800 cells were seeded in six-well plates and cultured at 37 °C under a humidified atmosphere containing 5 % CO2 for 2 weeks. The cells were then fixed with methyl alcohol for 30 min and stained with Giemsa solution for 10 min. Colonies were then counted and photographed. All experiments were performed in triplicate.
Cell scratch-wound assay
Cells were grown in 6-well plates until confluence. A wound was generated by scraping with a 10 ul tip. After 12 h, the cells in the wounded monolayer were photographed and cell migration was assessed by measuring gap sizes at multiple fields.
Tumor cell invasion assays
Boyden chambers with filter inserts (pore size, 8-μm) coated with Matrigel in 24-well dishes (BD Biosciences, USA) was performed to detect tumor cell invasion assays. Colon cancer cells with different treatment were then harvested, and 1 × 105 cells were seeded in serum-free medium into the upper chamber, whereas medium supplemented with 20 % fetal bovine serum was applied to the lower chamber as a chemoattractant to induce invasion. The migrated cells on the lower side of the filters were defined as invasive cells and counted at × 200 magnification in 10 different fields of each filter.
Confocal laser scanning microscopy
Cells were seeded into 35 mm glass bottom dishes with 10 mm microwell overnight. After permeabilized with 0.3 % Triton X-100 diluted in PBS for 15 min and then blocked with 5 % skimmed milk for 1 h, cells were incubated with primary antibody at 4 °C overnight. After washed with PBS three times for 5 min each time, cells were subjected to fluorescent secondary antibody at room temperature for 1 h. Before confocal microscopy analysis, cells were counterstained with DAPI.
Flow cytometric analysis
The apoptotic status was analyzed by using an Annexin V-APC/PI Apoptosis Kit (eBioscience, CA, USA) in accordance with the manufacturer’s instructions. Briefly, cells (1 × 106cells/mL) were collected by EDTA treatment and incubated with a mixture of annexin V-FITC and PI for 15 min at room temperature. The number of apoptotic cells was analyzed by flow cytometry (BD Accuri C6, USA).
Male BALB/c athymic nude mice (4–6 weeks old) purchased from the Institute of Zoology, Chinese Academy of Sciences of Shanghai. All mice were injected subcutaneously into the right side of back with 1.0 × 107 cells to establish the CRC xenograft model. One week after first injection, the two groups were sacrificed. Tumor diameters were measured at regular intervals with digital calipers, and tumor volume was calculated by the formula: tumor volume (mm3) = shorter diameter2 × longer diameter/2. To further investigate the metastasis effect of TIMP1 in vivo, we used a CRC metastasis model in male BALB/c-nu/nu mice. A total of 1 × 106 cells were infected with lenti-LUC virus and injected into the tail veins of nude mice. In weekly intervals, anesthetized mice were injected i.p. with D-luciferin (150 mg/kg) and imaged 10 min after injection using the IVIS Illumina System (Caliper Life Sciences).
Gene expression analysis was performed using R (http://www.r-project.org). Data from two experimental groups were compared with the t-test, chi-square test or Fisher’s exact test, as appropriate. Survival curves were drawn using the Kaplan-Meier method. The differences of the Kaplan-Meier survival curves were tested for statistical significance with the log rank test, and the 95 % confidence intervals were calculated. Multivariate analysis was done using the COX proportional hazard model and a forward stepwise method was used to bring variables into the model. Further statistical analyses were done using the SPSS 21.0 software (SPSS Inc.). A significant difference was declared if the p value from a two-tailed test was less than 0.05.
TIMP1 expression is significantly upregulated in human colon cancer
Correlation between TIMP1 expression and the clinical features of colon cancer
Expression of TIMP1 protein in normal mucosa, cancerous tissue, and LNM tissues
57 (60.6 %)
22 (23.4 %)
15 (16.0 %)
44 (46.8 %)
24 (25.5 %)
26 (27.7 %)
7 (19.4 %)
11 (30.6 %)
18 (50.0 %)
Correlation between TIMP1 expression and clinicopathological characteristics
(n = 94)
TIMP1 protein expression
(n = 44)
(n = 50)
43 (45.7 %)
21 (47.7 %)
22 (44.0 %)
51 (54.3 %)
23 (52.3 %)
28 (56.0 %)
47 (50.0 %)
23 (52.3 %)
24 (48.0 %)
47 (50.0 %)
21 (47.7 %)
26 (52.0 %)
25 (26.6 %)
12 (27.3 %)
13 (26.0 %)
9 (9.6 %)
5 (11.4 %)
4 (8.0 %)
10 (10.6 %)
6 (13.6 %)
4 (8.0 %)
50 (53.2 %)
21 (47.7 %)
29 (58.0 %)
T1 + T2
23 (24.5 %)
10 (22.7 %)
13 (26.0 %)
T3 + T4
71 (75.5 %)
34 (77.3 %)
37 (74.0 %)
51 (54.3 %)
29 (65.9 %)
22 (44.0 %)
N1 + N2
43 (45.7 %)
15 (34.1 %)
28 (56.0 %)
80 (85.1 %)
41 (93.2 %)
39 (78.0 %)
14 (14.9 %)
3 (6.8 %)
11 (22.0 %)
85 (90.4 %)
43 (97.7 %)
42 (84.0 %)
9 (9.6 %)
1 (2.3 %)
8 (16.0 %)
27 (28.8 %)
9 (20.4 %)
18 (36.0 %)
49 (52.1 %)
27 (61.4 %)
22 (44.0 %)
18 (19.1 %)
8 (18.2 %)
10 (20.0 %)
I + II
42 (44.7 %)
25 (56.8 %)
17 (34.0 %)
III + IV
52 (55.3 %)
19 (43.2 %)
33 (66.0 %)
Overexpression of TIMP1 predicts poor clinical outcome in human colon cancer
Kaplan-Meier survival analysis with the log-rank test for disease-free survival (DFS) and overall survival (OS) were undertaken to evaluate the relationship between TIMP1 expression and patient prognosis (Fig. 2c). The analysis revealed that patients with high levels of TIMP1 possessed shorter disease-free survival (DFS) time and overall survival (OS) time than patients with low levels of TIMP1 (p = 0.02 and p = 0.006, respectively).
Multivariate Cox proportional hazards analysis for disease-free survival (DFS) and overall survival (OS)
Multivariate analysis (DFS)
Multivariate analysis (OS)
AJCC stage (I/II vs. III/IV)
N stage (N0 vs. N1 + N2)
M stage (M0 vs. M1)
Vascular invasion (Yes vs. No)
TIMP1 expression (Negative vs. Positive)
Knockdown of TIMP1 inhibits the proliferation of colon cancer cell
Effects of suppression of TIMP1 in migration and invasion
TIMP1 plays an anti-apoptosis role in colon cells
Mechanisms of TIMP1 in colon cancer progression
To gain further insight into the biologic pathways involved in colon cancer pathogenesis, GSEA analysis was performed in TCGA datasets. Among all the predefined ‘oncogenic signature’ gene sets, the EMT pathway was identified with the strongest association with TIMP1 expression (Additional file 2: Figure S2). The other top-scoring hallmarks included angiogenesis, apoptosis, KRAS, hypoxia and so on. Several of these hallmarks are related to PI3K and MAPK signaling pathways, activation of which are frequently aberrantly activated in human cancers and contributes to enhance cell proliferation and survival. As shown in Fig. 5c and d, transfection with TIMP1-KD significantly decreased FAK, AKT, ERK1/2 and JNK phosphorylation in both HCT116 and SW620 cells; however, no detectable changes in the total levels of FAK, AKT, ERK1/2 and JNK were observed (Fig. 5d). Thus, the data suggested that the FAK-PI3K/AKT and MAPK pathway might participate in TIMP1-induced cell proliferation, metastasis and anti-apoptosis in colon cells. To illustrate its co-worked genes, PPIs network was built from the STRING resource (Additional file 1: Figure S1). Result shows that TIMP1, was highly correlated with several stars molecules, such as MMPs, EGFR, JUN, TGF-β and SMADs, etc. This hints that TIMP1 would be a crucial marker which is valuable for further research.
The functional impact of TIMP1 knockdown in colon cell invasion in vivo
TIMP1, which is a kind of soluble protein release by endometrial cells, fibroblasts and cancer cells, has been demonstrated to be associated with poor prognosis for a variety of cancers [12, 23, 24]. To find the involvement of TIMP1 in colon cancer, public data, such as Oncomine and TCGA, was used to evaluate the expression of this gene in colon patients, and data from 94 patients with primary colon cancer also present with elevated levels of TIMP1 which has the potential to predict the survival rate of patients. In this study, analysis of TIMP1 expression level and patients’ clinical outcomes suggested that those with high TIMP1 expression had poorer survival than those with low TIMP1 expression. Remarkably, TIMP1 is a secretory protein that could be detected in blood and body fluid, thus making it a good potential tumor marker. However, the significance of TIMP1 and its mechanism of action in the progression of colon cancer have been rarely reported.
Despite some researches have proved that TIMP-1 has a major role as inhibitor of MMPs , its role in tumor invasion and metastasis appears to be more complex. It has been believed that TIMP-1 has a dual function, one of which is based on MMPs dependent anti-proteolytic activity with the other MMP-independent cell growth activity . In the present study, our experiments showed that depletion of TIMP1 could suppress colon cancer cell proliferation, migration and invasion in vitro, and suppress the tumorigenicity and metastasis of colon cells in vivo. In addition, TIMP1 could also increase anti-apoptosis of colon cancer in BAD mediated phosphoration pathway. These results suggest that TIMP1 plays an important role in proliferation, invasion and metastasis of colon cancer and that TIMP1 may be a crucial therapeutic target.
To find the involved mechanism of TIMP1 in colon cancer, public data, such as TCGA, and high throughput analysis, such as STRING and GSEA was used to locate the pathway and correlated molecules which are related to TIMP1. These bioinformatics significantly pointed the function of TIMP1 to EMT, apoptosis and several other crucial pathways. To validate these predictions, biological experiment was conducted. We showed that TIMP1 overexpression is associated with constitutive activation of FAK, a signaling molecule known to be critical to the cell survival pathway . FAK was shown to be the upstream regulator of the PI3K-AKT pathway [28, 29]. Phosphorylation of AKT could upregulate cyclin D1 and downregulate the cyclin D kinase (CDK) inhibitors p21 and p27, which promotes cell cycle progression. Besides, AKT phosphorylates BAD, which no longer interacts with Bcl-2 (anti-apoptotic members of the bcl-2 family), resulting in Bcl-2 activation. Similarly, MAPK family can also phosphorylate BAD protein, resulting in release of anti-apoptotic Bcl-2 in the cells (Additional file 3: Figure S3). Although TIMP1 could inhibit MMP facilitated breakdown of the ECM and was thought to be metastasis inhibitor , we found that TIMP1 could promote colon cancer invasion and metastasis by development of EMT transcription factors such as SLUG, leading to downregulation of epithelial marker E-cadherin and upregulation of mesenchymal marker fibronectins. In conclusion, by analyzing data from public and our own, we clearly illustrated that TIMP1 actually plays a great role in cancer progression, which is independent of MMP, and the FAK - PI3K/AKT and MAPK pathway might play an important role in TIMP1-induced cell proliferation, metastasis and anti-apoptosis. Besides, the paradoxical report of TIMP1 as an inhibitor of MMPs and poor prognosis marker of colon cancer as well, could be explained by its MMP independent function, which suggests the elevation of TIMP1 in colon cancer is not a feedback regulation of the upregulation of MMP, but is a vitally important and self-governed effect in colon cancer. All these results provided a new method to make prognosis prediction and suggested that TIMP1 could be a therapeutic marker.
In summary, the present study identified that TIMP1 is overexpressed in colon tumor samples and that dysregulated TIMP1 expression, which occurs frequently in colon cancer, leads to tumor proliferation, metastasis and anti-apoptosis by FAK-PI3K/AKT and MAPK pathway. In animal experiments, the in vivo tumorigenicity and metastasis were weakened effectively by downregulation of TIMP1. These results suggest that TIMP1 signaling is a promising new molecular target for novel preventive and therapeutic strategies for this malignancy, and TIMP1 expression is critical for the progression and invasiveness of colon cancer. However, further explorations are needed to fully elucidate the molecular mechanisms governing TIMP1 gene dysregulation and its role in colon cancer progression.
This project was supported by the funds: National Nature Science Foundation of China (81472241 and 81270557).
This work was supported by grants from the National Nature Science Foundation of China (81472241 and 81270557).
Availability of data and materials
Please contact author for data requests.
Conceived and designed the study: JC, XLW and GHS; Collected tissue samples: CZZ and ZWW; Performed the histopathological analysis: SFX, TJ and LLW; Performed cell culture and laboratory analysis: YPW, CX and TZ; Performed the animal experiment: TZ, XS and LZ; Analyzed the data: JC; Wrote and revised the manuscript: GHS, YPW, JC and XLW. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethical approval and consent to participate
Ethical approval was given by the medical ethics committee of Shanghai General Hospital with the following reference number: 2014KY023.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.View ArticlePubMedGoogle Scholar
- De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P, et al. Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep. 2015;34(3):1087–96.PubMedGoogle Scholar
- Chen J, Tang H, Wu Z, Zhou C, Jiang T, Xue Y, et al. Overexpression of RBBP6, alone or combined with mutant TP53, is predictive of poor prognosis in colon cancer. PLoS One. 2013;8(6):e66524.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang X, Fan J, Yu F, Cui F, Sun X, Zhong L, et al. Decreased MALL expression negatively impacts colorectal cancer patient survival. Oncotarget. 2016;7(16):22911–27.PubMedPubMed CentralGoogle Scholar
- Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem. 2012;287(19):15935–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Bao W, Fu HJ, Jia LT, Zhang Y, Li W, Jin BQ, et al. HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys. 2010;499(1–2):49–55.View ArticlePubMedGoogle Scholar
- Wurtz SO, Moller S, Mouridsen H, Hertel PB, Friis E, Brunner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics. 2008;7(2):424–30.View ArticlePubMedGoogle Scholar
- Wurtz SO, Schrohl AS, Mouridsen H, Brunner N. TIMP-1 as a tumor marker in breast cancer--an update. Acta Oncol. 2008;47(4):580–90.View ArticlePubMedGoogle Scholar
- Nalluri S, Ghoshal-Gupta S, Kutiyanawalla A, Gayatri S, Lee BR, Jiwani S, et al. TIMP-1 inhibits apoptosis in lung adenocarcinoma cells via interaction with Bcl-2. PLoS One. 2015;10(9):e0137673.View ArticlePubMedPubMed CentralGoogle Scholar
- Fu ZY, Lv JH, Ma CY, Yang DP, Wang T. Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-small ka, CyrillicB pathway. Biomed Pharmacother. 2011;65(3):163–7.View ArticlePubMedGoogle Scholar
- Toricelli M, Melo FH, Peres GB, Silva DC, Jasiulionis MG. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer. 2013;12:22.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang YY, Li L, Zhao ZS, Wang HJ. Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J Surg Oncol. 2013;11:81.View ArticlePubMedPubMed CentralGoogle Scholar
- Hawthorn L, Stein L, Varma R, Wiseman S, Loree T, Tan D. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck. 2004;26(12):1069–83.View ArticlePubMedGoogle Scholar
- Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, et al. Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 2016;11(5):3354–60.PubMedPubMed CentralGoogle Scholar
- Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Matthai E, et al. LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer. Transl Oncol. 2013;6(2):99–103.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen J, Lu H, Yan D, Cui F, Wang X, Yu F, et al. PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy. Oncotarget. 2015;6(1):355–67.PubMedGoogle Scholar
- Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gremy G, et al. Deciphering cellular states of innate tumor drug responses. Genome Biol. 2006;7(3):R19.View ArticlePubMedPubMed CentralGoogle Scholar
- Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One. 2010;5(10):e13091.View ArticlePubMedPubMed CentralGoogle Scholar
- Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010;27(2):83–90.View ArticlePubMedGoogle Scholar
- Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 2003;424(6951):952–6.View ArticlePubMedGoogle Scholar
- Yan J, Xiang J, Lin Y, Ma J, Zhang J, Zhang H, et al. Inactivation of BAD by IKK inhibits TNFalpha-induced apoptosis independently of NF-kappaB activation. Cell. 2013;152(1–2):304–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351–65.View ArticlePubMedGoogle Scholar
- Bjerre C, Vinther L, Belling KC, Wurtz SO, Yadav R, Lademann U, et al. TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression. Tumour Biol. 2013;34(6):3839–51.View ArticlePubMedGoogle Scholar
- Peng L, Yanjiao M, Ai-guo W, Pengtao G, Jianhua L, Ju Y, et al. A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells. Biochem Biophys Res Commun. 2011;409(2):344–9.View ArticlePubMedGoogle Scholar
- Stilley JA, Sharpe-Timms KL. TIMP1 contributes to ovarian anomalies in both an MMP-dependent and -independent manner in a rat model. Biol Reprod. 2012;86(2):47.View ArticlePubMedGoogle Scholar
- Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, et al. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol. 2004;78(11):5934–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Kostourou V, Lechertier T, Reynolds LE, Lees DM, Baker M, Jones DT, et al. FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun. 2013;4:2020.View ArticlePubMedPubMed CentralGoogle Scholar
- Oudart JB, Doue M, Vautrin A, Brassart B, Sellier C, Dupont-Deshorgue A, et al. The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through alphavbeta3 integrin interaction. Oncotarget. 2016;7(2):1516–28.PubMedGoogle Scholar
- Kapur R, Cooper R, Zhang L, Williams DA. Cross-talk between alpha(4)beta(1)/alpha(5)beta(1) and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signaling pathways. Blood. 2001;97(7):1975–81.View ArticlePubMedGoogle Scholar
- Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997;389(6646):77–81.View ArticlePubMedGoogle Scholar